TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02527577
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: injection Hour (H) 0, H12 ; H24, H36 ; H48
Study: NCT02205840
Drug: Vehicle
Normalized name: Drug vehicle
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 drop in each eye
Study: NCT00870584
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo was supplied as a lyophilized, sterile powder in a single-use, 5 mL vial. The vial was designed to deliver 150 mg (1.2 mL) of placebo for subcutaneous (s.c.) administration after reconstitution with 1.4 mL sterile water for injection. Doses of more than 150 mg were divided among multiple injection sites to limit injections to not more than 150 mg per site.
Study: NCT00093249
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (20% lipid emulsion - vehicle) will be administered intravenously in a fashion identical to clevidipine as described above.
Study: NCT00419445
Drug: GTS21/Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04507282
Drug: LMWH
Normalized name: Low-molecular-weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: COVID 19 positive patients anticogulation level, subprophylactic level and prophylactic level
Study: NCT02802917
Drug: SPF 50 Y49 091 (BAY 987516)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 μL of the appropriate test or control article were instilled into the lower conjunctival sac of the eye.
Study: NCT02802917
Drug: SPF 50 X15 158 (BAY 987516)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 μL of the appropriate test or control article were instilled into the lower conjunctival sac of the eye.
Study: NCT02802917
Drug: SPF 50 X15 160 (BAY 987516)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 μL of the appropriate test or control article were instilled into the lower conjunctival sac of the eye.
Study: NCT02802917
Drug: SPF 50 X57 162 (BAY 987516)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 μL of the appropriate test or control article were instilled into the lower conjunctival sac of the eye.
Study: NCT02121665
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each placebo lozenge contains all excipients except the active constituent (Lactobacillus brevis CD2)
Study: NCT02594566
Drug: CyMVectin
Normalized name: Cydectin
Approvals — FDA: no, EMA: no, PMDA: no
Description: CyMVectin will be delivered by unilateral intramuscular (IM) injection at Day 0, Day 28(+4 days), and Day 56 (+4 days) in alternating arms. Each dose of CyMVectin will be administered in a 1.0-mL volume
Study: NCT00304213
Drug: Testosterone
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00680394
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 800 buccal misoprostol + matching placebo or 1600 buccal misoprostol
Study: NCT00534313
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solution, intravenous, placebo (double dummy), monthly, short-term = 24 weeks (6 months)
Study: NCT00323830
Drug: Capecitabine, cisplatin, Radiotherapy (+/-)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capecitabine, cisplatin + Radiotherapy (randomized)
Study: NCT01058707
Drug: MLN0128
Approvals — FDA: no, EMA: no, PMDA: no
Description: MLN0128 capsules
Study: NCT00795678
Drug: capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine is an oral prodrug of 5 deoxy-5-fluorouridine (5DFRU) that is converted to 5-fluorouracil (5-FU). 5-FU is metabolized to 5-fluoro-2-deoxyuridine monophosphate (fDUMP) and 5-fluorouridine triphosphage (FUTP) which cause cell injury. Capecitabine is supplied in 150 mg (light peach colored) and 500 mg tablets (film coated)and will be administered pre-operatively.
Study: NCT00795678
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide is biotransformed principally in the liver to active alkylating metabolites that cross-link tumor cell DNA. Cyclophosphamide is supplied in 100 mg, 200 mg, 500 mg and 1 gram and 2 gram vials as a white powder. The drug should be reconstituted with Sterile Water for Injection, USP, and may be diluted in either normal saline or D5W. Cyclophosphamide will be mixed in 250 mL of D5W and infused over 30 minutes prior to surgery.
Study: NCT00795678
Drug: doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Doxorubicin is an anthracycline anticancer agent which mediates tumoricidal effects by intercalating into double-stranded DNA and producing structural changes that disrupt DNA and RNA synthesis. Doxorubicin is supplied in 10, 20, and 50 mg single use vials, and 150 mg multidose vials as a red-orange, lyophilized power which has a storage stability of a least two years. The dose will be given 60mg/m2 over 15 minutes of time pre-operatively.
Study: NCT01947855
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablet matching Empagliflozin low dose
Study: NCT01947855
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablet matching Empagliflozin high dose
Study: NCT03225313
Drug: Normal Saline Flush, 0.9% Injectable Solution_#5
Approvals — FDA: no, EMA: no, PMDA: no
Description: injected into rectus sheath using ultrasound \& locally surrounding the hernia
Study: NCT00883129
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 12 months of oral cyclophosphamide, up to a maximal dose of 2 mg/kg daily as tolerated
Study: NCT00883129
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12 months of placebo will be delivered to participants in the Cyclophosphamide arm during the second year in order to maintain the blind with the Mycophenolate arm, which receives drug for the entire 2 years.
Study: NCT01477775
Drug: Oral P2Y12 receptor blocker
Approvals — FDA: no, EMA: no, PMDA: no
Description: Free choice among clopidogrel, prasugrel or ticagrelor
Study: NCT01477775
Drug: Customized choice for the oral P2Y12 receptor blocker
Approvals — FDA: no, EMA: no, PMDA: no
Description: one drug among clopidogrel, prasugrel or ticagrelor based on an algorithm integrating phenotype information.
Study: NCT02831478
Drug: BAY987517
Approvals — FDA: no, EMA: no, PMDA: no
Description: Applied liberally to the skin (Formulation: RB# Z16-071)
Study: NCT01898884
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04583592
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered as oral round tablets. Study dose: Two placebo tablets taken orally 4 times daily for 14 days.
Study: NCT03036488
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: On Day 1 of Cycles 5-8 of the neoadjuvant phase of the study; IV injection.
Study: NCT03036488
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: On Day 1 of Cycles 5-8 of the neoadjuvant phase of the study; IV infusion.
Study: NCT03036488
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: normal saline solution or dextrose: On Day 1 of each cycle in the neoadjuvant and adjuvant phases of the study for a total of 17 cycles; IV infusion
Study: NCT02983773
Drug: THC 3.0%
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 smoked marijuana cigarette with 3.0% THC
Study: NCT02983773
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 smoked placebo marijuana cigarette
Study: NCT03894007
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 600 mg/m2 iv, day 1 every third week, 3 courses preoperatively
Study: NCT02255435
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03161379
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide 200 mg/m2 will be administered one day prior to vaccination (day 0). First dose will be given within 4 to 6 weeks after chemotherapy. 3 weeks after the first dose of immunotherapy the second dose will be given.
Study: NCT01343641
Drug: MK-0677
Normalized name: vitamin MK 7
Approvals — FDA: no, EMA: no, PMDA: no
Description: The oral agent MK-677 is spiropiperidine, Merck L-163 191, GH secretagogue ghrelin mimetic which increases GH and IGF-I secretion, fat free mass and energy expenditure76-79. It is produced by Merck \& Co, Inc.
Study: NCT01343641
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactive Pill used as a comparator
Study: NCT01934647
Drug: MK-8892
Normalized name: vitamin MK 7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral capsule with 1 mg, 4 mg, or 8 mg of MK-8892
Study: NCT03930264
Drug: Azathioprine 50Mg Tab
Normalized name: AZATHIOPRINE 50MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: tablet
Study: NCT03930264
Drug: Azathioprine 10mg/mL oral suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral suspension
Study: NCT01638442
Drug: CHR-2797
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two 60 mg capsules (120 mg dose) of CHR-2797 administered orally with 240 mL room temperature tap water after an approximately 10 hour fast.
Study: NCT01638442
Drug: CHR-2797
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two 60 mg capsules (120 mg dose) of CHR-2792 administered orally with 240 mL room temperature tap water within 30 minutes of receiving a high-fat meal.~--------------------------------------------------------------------------------
Study: NCT04249232
Drug: Placebo prefilled injector pen
Approvals — FDA: no, EMA: no, PMDA: no
Description: prefilled injector pen to deliver inactive solution daily subcutaneously
Study: NCT03830905
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive Placebo once a day during 3 days
Study: NCT01588418
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo was administered in random order 30 min before OGTT-PET study in the same subject
Study: NCT03607513
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo to JNJ-64264681 will be administered as oral solution.
Study: NCT01012219
Drug: Comparator: aspirin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 81 mg oral tablet once daily for 7 days
Study: NCT01012219
Drug: Comparator: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo oral tablet once daily for 7 days
Study: NCT01710137
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02263352
Drug: Lycored soft gels Jagsonpal Pharma, Systemic 8mgms/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lycopene 8mgms taken orally ,one per day for two months.
Study: NCT01206322
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The acute effects of intranasal sterile saline.
Study: NCT01250496
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching 0.9 Normal Saline (sterile salt water)administered intravenously.
Study: NCT01542567
Drug: Abitren
Approvals — FDA: no, EMA: no, PMDA: no
Description: SUPPOSITORIES 50 Mg 2 SUPPOSITORIES A WEEK
Study: NCT01542567
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo suppositories
Study: NCT03935568
Drug: PU-AD
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 3 cohorts receiving a single oral dose of PU-AD at one time.
Study: NCT03935568
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 cohorts receiving a single oral dose of Placebo at one time
Study: NCT03935568
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 cohorts receiving multiple oral dose of Placebo at one time
Study: NCT03935568
Drug: PU-AD
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2 cohorts receiving multiple oral dose of PU-AD at one time
Study: NCT01697410
Drug: Norepinephrine
Normalized name: Norepinephrine
DrugBank: Norepinephrine (DB00368)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: continuous infusion with dose 7.5ug/min-30ug/min,modified acorrding to blood pressure
Study: NCT00205270
Drug: Influenza vaccine
Normalized name: Influenza vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: influenza vaccine 0.5 ml intramuscularly each season
Study: NCT01863160
Drug: 0.1% ZEP-3 cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical application of 250mg ZEP-3 cream (0.1%) vs. placebo 4 times daily The IP is applied to in advanced demarcated sites in a dose escalating mode to 3 different treatment area sizes: small area of 2x1 cm (2 cm2), medium area of 2x5 cm (10 cm2), and large area of 4x5 cm (20 cm2).~The IP ZEP-3 cream will be applied on both ventral forearms (one application site per forearm) in a non-occlusive mode, spread and rubbed over the demarcated area.~* Right arm, single treatment area - ZEP-3 (0.1%)~* Left arm, single treatment area - Placebo cream
Study: NCT00027573
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00027573
Drug: methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01262274
Drug: Anastrozole plus tegafur-uracil
Normalized name: tegafur / uracil
Approvals — FDA: no, EMA: no, PMDA: no
Description: ANA is given 1mg daily for 24 weeks. UFT is given by 270mg/m2 twice a day for 24 weeks.
Study: NCT01788813
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nasal Spray Solution, to be given intranasal, once weekly for 8 weeks
Study: NCT00544349
Drug: leucovorin calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01371006
Drug: low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: efavirenz single dosing once daily
Study: NCT01371006
Drug: normal dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: efavirenz once daily
Study: NCT01371006
Drug: low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Efavirenz single dosing once daily
Study: NCT00503035
Drug: Celecoxib
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 400 mg by mouth twice daily x 6 months
Study: NCT01680198
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02936661
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00522925
Drug: PS433540
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200mg capsule, once daily for 28 days
Study: NCT00522925
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo capsule, once daily for 28 days
Study: NCT00522925
Drug: PS433540
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500mg capsule, once daily for 28 days
Study: NCT03530007
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: normal saline used for prevention of spinal shivering
Study: NCT03963167
Drug: BDP/FF/G fixed combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed combination of Inhaled Corticosteroid (ICS) / Long-acting β2-agonist (LABA) / long-acting muscarinic antagonist (LAMA) that contains Beclometasone dipropionate (BDP), Formoterol fumarate (FF) and Glycopyrronium (G).
Study: NCT04527159
Drug: Fluoraphat Pro / VivaSens
Approvals — FDA: no, EMA: no, PMDA: no
Description: desensitizing agents for treatment of dentinal hypersensitivity
Study: NCT02216214
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral tablet
Study: NCT04495296
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine will be administered by specified doses on specified day
Study: NCT03264118
Drug: Toluidine Blue O
Normalized name: Toluidine Blue O
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antimicrobial photodynamic therapy with toluidine blue O (10mg/ml) and red laser.
Study: NCT02826174
Drug: Anti-Rejection Agents
Normalized name: Anti Bac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-Rejection Agents for both groups
Study: NCT02826174
Drug: Anti-Inflammatory Agents
Normalized name: Surpass Anti-Inflammatory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-Inflammatory Agents for both groups
Study: NCT01757873
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01598740
Drug: CLP
Normalized name: Endopeptidase Clp
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral administration
Study: NCT01598740
Drug: Spironolactone
Normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: oral administration
Study: NCT02992808
Drug: HP-HMG
Normalized name: HP 502
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01317550
Drug: Minocycline
Normalized name: Minocycline
DrugBank: Minocycline (DB01017)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 100 mg by mouth twice a day for a 10 week cycle.
Study: NCT03504956
Drug: Contrast
Normalized name: CONTRAST MEDIA
Approvals — FDA: no, EMA: no, PMDA: no
Description: The intravenous gadolinium based contrast agent to be used in this study is Gadavist (up to 0.2 mmol/kg).
Study: NCT03504956
Drug: Beta blocker
Normalized name: Beta blocker
Approvals — FDA: no, EMA: no, PMDA: no
Description: Based upon the focus of the study at the time of the scan, a beta- blocker (metoprolol), in pill form based upon blood pressure and heart rate, may be administered to some subjects to improve the heart's ability to relax and slow the heart rate. The slower heart rate may improve image quality and lessen motion artifact.
Study: NCT00442572
Drug: PEGASYS [peginterferon alfa-2a]
Approvals — FDA: no, EMA: no, PMDA: no
Description: There were 4 treatment cycles of continuous intermittent treatment with Peginterferon alfa-2a. Each cycle consisted of 12 weeks injection treatment with Peginterferon alfa-2a 135 micrograms in 0.5 ml solution in prefilled syringes, applied once weekly subcutaneously and followed by 12 weeks period without treatment.
Study: NCT04044690
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: contains 2% human albumin, similar excipients as IgPro20 (Hizentra), same volume, same duration, administered subcutaneously
Study: NCT04501861
Drug: Norepinephrine
Normalized name: Norepinephrine
DrugBank: Norepinephrine (DB00368)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Norepinephrine (4 mg/250ml in 5% dextrose) were stored in pre-mixed bags in the operating room, readily available for continuous infusion administration via pre-programed infusion pumps
Study: NCT01987570
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00790972
Drug: Sinofresh
Normalized name: MENTHA PIPERITA 3 [hp_X] in 100 mL ORAL SPRAY [ANTISEPTIC SINOFRESH KOOL BLAST THROAT]
Approvals — FDA: no, EMA: no, PMDA: no
Description: two sprays in each nostril three times daily for one week
Study: NCT00790972
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: two sprays in each nostril three times daily for one week
Study: NCT03095196
Drug: HF drugs
Approvals — FDA: no, EMA: no, PMDA: no
Description: full medical therapy to treat HF symptoms and its progression.
Study: NCT00125125
Drug: Fluvastatin
Normalized name: Fluvastatin
DrugBank: Fluvastatin (DB01095)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00812045
Drug: AZD1236
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral tablet, 75 mg twice daily during 4 weeks
Study: NCT00812045
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00154089
Drug: EM-1421
Approvals — FDA: no, EMA: no, PMDA: no
Description: EM-1421 administered intravaginally every 3 weeks as 45 mg (1% w/w) EM-1421 or 90 mg (2% w/w) EM-1421
Study: NCT01649999
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral
Study: NCT01588678
Drug: DS-3078a
Normalized name: Uretron DS
Approvals — FDA: no, EMA: no, PMDA: no
Description: DS-3078a will be administered as oral capsules once daily and will be supplied in 5, 20, 50, and 150 mg capsules.
Study: NCT03952377
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transforaminal Epidural Injection
Study: NCT01676636
Drug: Unflavoured Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: The unflavoured powder with suspension agent will be tasteless and consumed by either adding it to a semi-solid food or drink of one's choosing. Appropriate foods for mixing with the powder will be at the discretion of the participants. This vehicle was selected on the basis that it would be easy to swallow, given the nausea associated with pregnancy. A similar product is Sprinkles, a multiple micronutrient powder developed at SickKids by Dr. Zlotkin.
Study: NCT01676636
Drug: Flavoured Powder
Normalized name: benzocaine
DrugBank: Benzocaine (DB01086)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The flavoured powder with suspension agent will be consumed by adding it to clean water with a meal. This vehicle was also selected on the basis that it would be easy to swallow, given the nausea associated with pregnancy. Similar products include oral rehydration salts or artificial juice flavour crystals.
Study: NCT00891540
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isotonic NaCl
Study: NCT04958460
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administrated 1 packet of maltodextrin (as placebo of Bf-688) in the morning and evening
Study: NCT01466829
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo; saline injection.
Study: NCT00004913
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00004913
Drug: leucovorin calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00557700
Drug: Administration of placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration of placebo
Study: NCT03294382
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1 mL normal saline, injected in two points at one side, 0.05 mL per point, local injection
Study: NCT04509440
Drug: corticosteroid with local anaesthetics (40 mg of triamcinolone acetonide (40 mg/ml) with 1.5 ml mepivacaine HCl 3% )
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticosteroid with local anaesthetics (40 mg of triamcinolone acetonide (40 mg/ml) with 1.5 ml mepivacaine HCl 3% ) (local anesthetic). They were given as a single local soft tissue injection at the point of maximal tenderness on the lower medial aspect of the knee region.